Doseology Settles Debt with Share Issuance, Director Resigns
Doseology Sciences Inc. announced plans to issue shares valued at approximately $13,548 to settle consulting fees. The company also disclosed the resignation of a board director.
Doseology Sciences Inc. will issue approximately 75,268 common shares to settle $13,548.39 in accrued consulting fees owed to a former consultant. The settlement, proposed at a deemed price of $0.18 per share, is expected to be completed around September 30, 2026, pending regulatory approvals.
In a separate announcement, Daniel Vice has resigned from his position as a director of the company, effective September 17, 2026. The company offered no further details on the director's departure.
Doseology Sciences focuses on the development of oral pouch products containing stimulants and cognitive support ingredients. The company positions these products as a discreet and smokeless alternative to traditional stimulant delivery methods, such as smoking or vaping.
The oral stimulant pouch market is experiencing growth as consumers seek convenient and innovative product formats. Doseology aims to capitalize on this trend with its range of vapor-free and smokeless products.
The company's shares are traded on the Canadian Securities Exchange (CSE: MOOD), OTCQB (DOSEF), and Frankfurt Stock Exchange (FSE: VU70).